New pill shows promise for schizophrenia psychosis
NCT ID NCT01499563
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia during an acute psychotic episode. 335 adults with schizophrenia were randomly assigned to receive ITI-007, a placebo, or an active control for 28 days. The main goal was to measure changes in symptom severity using a standard rating scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ITI-007
What this could lead to
If successful, this could lead to a new medication to ease schizophrenia symptoms during acute episodes.
What could go wrong
This is an early phase 2 trial, so results may not confirm effectiveness. The drug could also have side effects or fail to outperform placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site
Little Rock, Arkansas, United States
-
Clinical Site
Garden Grove, California, United States
-
Clinical Site
Atlanta, Georgia, United States
-
Clinical Site
Rockville, Maryland, United States
-
Clinical Site
St Louis, Missouri, United States
-
Clinical Site
Willingboro, New Jersey, United States
-
Clinical Site
Philadelphia, Pennsylvania, United States
-
Clinical Site
Austin, Texas, United States